Corbus Pharmaceuticals, Inc.
100 River Ridge Drive
Norwood
Massachusetts
02062
United States
Tel: 617-963-0100
Fax: 617-663-6085
Website: http://www.corbuspharma.com/
97 articles with Corbus Pharmaceuticals, Inc.
-
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
5/11/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.
-
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
5/10/2022
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
-
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
3/11/2022
Corbus Pharmaceuticals Holdings, Inc. today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET.
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
3/8/2022
Corbus Pharmaceuticals Holdings, Inc., an immunology company, provided corporate updates and reported financial results for the fourth quarter and year-end of 2021.
-
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
12/7/2021
Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose.
-
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11/11/2021
Corbus Pharmaceuticals Holdings, Inc. will participate in a fireside chat at the Jefferies London Healthcare Conference being held virtually and in person November 16-19, 2021.
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Funds will also be utilized to enhance Corbus’ pipeline of novel endocannabinoid system-targeting drug candidates, and the company’s workforce will be reduced by up to 54%.
-
Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis.
-
Clinical Catch-Up: September 7-11
9/14/2020
It was a busy week for clinical trial updates. Here’s a look. -
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).
-
Clinical Catch-Up: August 10-14
8/17/2020
It was a very busy week for clinical trial updates. Here’s a look. -
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
BioSpace Movers & Shakers, May 29
5/29/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
12/17/2018
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30%
-
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
8/8/2018
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and Japan
-
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
6/21/2018
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and mechanisms